197 related articles for article (PubMed ID: 31037142)
1. An Optogenetic Controllable T Cell System for Hepatocellular Carcinoma Immunotherapy.
Zhao B; Wang Y; Tan X; Zheng X; Wang F; Ke K; Zhang C; Liao N; Dang Y; Shi Y; Zheng Y; Gao Y; Li Q; Liu X; Liu J
Theranostics; 2019; 9(7):1837-1850. PubMed ID: 31037142
[No Abstract] [Full Text] [Related]
2. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
Li D; Li N; Zhang YF; Fu H; Feng M; Schneider D; Su L; Wu X; Zhou J; Mackay S; Kramer J; Duan Z; Yang H; Kolluri A; Hummer AM; Torres MB; Zhu H; Hall MD; Luo X; Chen J; Wang Q; Abate-Daga D; Dropulic B; Hewitt SM; Orentas RJ; Greten TF; Ho M
Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001
[TBL] [Abstract][Full Text] [Related]
3. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
4. Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo.
Liu Y; Butterfield LH; Fu X; Song Z; Zhang X; Lu C; Ding G; Wu M
Int J Oncol; 2011 Jul; 39(1):245-53. PubMed ID: 21491085
[TBL] [Abstract][Full Text] [Related]
5. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
6. Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.
Batra SA; Rathi P; Guo L; Courtney AN; Fleurence J; Balzeau J; Shaik RS; Nguyen TP; Wu MF; Bulsara S; Mamonkin M; Metelitsa LS; Heczey A
Cancer Immunol Res; 2020 Mar; 8(3):309-320. PubMed ID: 31953246
[TBL] [Abstract][Full Text] [Related]
7. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
8. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
9. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy.
Zhao Y; Shuen TWH; Toh TB; Chan XY; Liu M; Tan SY; Fan Y; Yang H; Lyer SG; Bonney GK; Loh E; Chang KTE; Tan TC; Zhai W; Chan JKY; Chow EK; Chee CE; Lee GH; Dan YY; Chow PK; Toh HC; Lim SG; Chen Q
Gut; 2018 Oct; 67(10):1845-1854. PubMed ID: 29602780
[TBL] [Abstract][Full Text] [Related]
10. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.
Liu Y; Di S; Shi B; Zhang H; Wang Y; Wu X; Luo H; Wang H; Li Z; Jiang H
J Immunol; 2019 Jul; 203(1):198-207. PubMed ID: 31142602
[TBL] [Abstract][Full Text] [Related]
11. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma.
Liu G; Rui W; Zheng H; Huang D; Yu F; Zhang Y; Dong J; Zhao X; Lin X
Eur J Immunol; 2020 May; 50(5):712-724. PubMed ID: 31981231
[TBL] [Abstract][Full Text] [Related]
12. Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells.
Zhang Q; Yuan XF; Lu Y; Li ZZ; Bao SQ; Zhang XL; Yang YY; Fan DM; Zhang YZ; Wu CX; Guo HX; Zhang YJ; Ye Z; Xiong DS
Int J Cancer; 2017 Oct; 141(7):1445-1457. PubMed ID: 28643325
[TBL] [Abstract][Full Text] [Related]
13. PiggyBac-engineered T cells expressing a glypican-3-specific chimeric antigen receptor show potent activities against hepatocellular carcinoma.
Wang P; Qin W; Liu T; Jiang D; Cui L; Liu X; Fang Y; Tang X; Jin H; Qian Q
Immunobiology; 2020 Jan; 225(1):151850. PubMed ID: 31522780
[TBL] [Abstract][Full Text] [Related]
14. Genetically engineered recombinant adenovirus expressing interleukin‑2 for hepatocellular carcinoma therapy.
Sun Y; Wu H; Chen G; Huang X; Shan Y; Shi H; Zhang Q; Zheng Y
Mol Med Rep; 2018 Jan; 17(1):300-306. PubMed ID: 29115604
[TBL] [Abstract][Full Text] [Related]
15. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy.
Patel K; Lamm R; Altshuler P; Dang H; Shah AP
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32942580
[TBL] [Abstract][Full Text] [Related]
17. Recurrent hepatocellular carcinoma cells with stem cell-like properties: possible targets for immunotherapy.
Xu X; Xing B; Hu M; Xu Z; Xie Y; Dai G; Gu J; Wang Y; Zhang Z
Cytotherapy; 2010 Apr; 12(2):190-200. PubMed ID: 19929456
[TBL] [Abstract][Full Text] [Related]
18. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
19. In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells.
Leboeuf C; Mailly L; Wu T; Bour G; Durand S; Brignon N; Ferrand C; Borg C; Tiberghien P; Thimme R; Pessaux P; Marescaux J; Baumert TF; Robinet E
Mol Ther; 2014 Mar; 22(3):634-644. PubMed ID: 24445938
[TBL] [Abstract][Full Text] [Related]
20. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
